Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 6/20 | 0.60 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3545741 | 0.87 | RXFP1 (0.55) | ADORA1SQORADORA2AHSD17B10ADRA2A | |
| SCHEMBL26632998 | 0.84 | SQOR (0.57) | ADORA1SQORADORA2AHSD17B10ADRA2A | |
| SCHEMBL7024723 | 0.84 | ALDH1A1 (0.67) | ADORA1SQORADORA2AHSD17B10KDM4E | |
| SCHEMBL3551822 | 0.83 | ADORA1 (0.52) | ADORA1SQORADORA2AHSD17B10ADRA2A | |
| SCHEMBL28379366 | 0.81 | KDM4E (0.58) | ADORA1SQORADORA2AHSD17B10ADRA2A | |
| SCHEMBL7018629 | 0.81 | ADORA1 (0.54) | ADORA1ADORA2AHSD17B10ADRA2AHTT | |
| SCHEMBL7016201 | 0.80 | ADORA1 (0.68) | ADORA1ADORA2AHSD17B10ADRA2AHTT | |
| SCHEMBL3356574 | 0.79 | ADORA1 (0.61) | ADORA1SQORADORA2AADORA3MEN1 | |
| SCHEMBL244652 | 0.79 | ADORA1 (0.83) | ADORA1 | |
| SCHEMBL6440940 | 0.78 | HSD17B10 (0.62) | ADORA1ADORA2AHSD17B10HTTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368320-B1 | SUBSTITUTED 2-OXY-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-08-16 | — | — | EP | claimed |
| US-7855219-B2 | Substituted 2-oxy-3,5-dicyano-4aryl-6-aminopyridines and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-21 | — | — | US | disclosed |
| US-7855219-B2 | Substituted 2-oxy-3,5-dicyano-4aryl-6-aminopyridines and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-21 | — | — | US | disclosed |
| US-7855219-B2 | Substituted 2-oxy-3,5-dicyano-4aryl-6-aminopyridines and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-21 | — | — | US | disclosed |
| EP-1368320-B1 | SUBSTITUTED 2-OXY-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-08-16 | — | — | EP | disclosed |
| US-20050261502-A1 | Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-11-24 | — | — | US | disclosed |
| EP-1368320-A1 | SUBSTITUTED 2-OXY-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002070484-A1 | SUBSTITUTED 2-OXY-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261502-A1 | Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof | ADORA2A, ADORA3, ADORA1 | ADORA1 3/4885SQOR 1413/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.